Home > 2022 > December

Month: December 2022

Testing of Diethylene Glycol (DEG) & Ethylene Glycol (EG) at Central Drug Laboratory, Karachi

Asad Ullah Drugs, General, Regulatory Updates

The Central Drug Testing Laboratory (CDL), Karachi, is providing facilities for testing of solvents (Glycerin, Propylene Glycol, and Sorbitol) used in oral preparations for the presence of any toxic impurities (e.g., Diethylene Glycol (DEG) and Ethylene Glycol (EG)) to the manufacturers and importers of pharmaceutical products. DRAP has already issued advisories and directions via letter F. No. 6-30/2022-QA dated October 21, 2022 and December 13, 2022 to the stakeholders for compliance.

Central Drug Laboratory has issued following guidance steps for manufacturers and importers for availing these facilities.

Sampling:

  1. Sampling should be made on the basis of √n + 1
  2. A composite of the quantity drawn should be made
  3. Divide this composite in three equal parts (approximately 30ml in each bottle)

Fee:

  1. Fee voucher to be generated on DRAP’s fee portal fee.dra.gov.pk by completing following steps:-
  2. a. Create Login / Enter Your Login Details
    b. Click on Generate Fee
    c. Select Division = Central Drugs Laboratory
    d. Select Payment Head = Central Drugs Testing laboratory
    e. Fee = Gas Chromatography
    f. Enter Details
  3. Fee for each batch is Rs.23000/-

Document Required:

  1. Sampling Information Sheet.
  2. Certificate of Analysis by Manufacturer.
  3. Testing Request Letter.
  4. Copy of voucher paid in any branch of Allied bank.

Testing Time:

  1. The samples will be tested on the FIFO basis.

Dispatch of Samples

  1. Three bottles as mentioned under sampling per batch shall be sent to CDL along with the
    documents mentioned above.
  2. The firm is responsible to maintain the conditions of samples during transportation.
  3. Sample should be dispatch on following Address:-
    Director, Central Drugs Laboratory
    4-B, SMCHS, Block B, Karachi

For any further assistance, Please contact to

Director, Central Drugs Laboratory, 4-B, SMCHS, Block B, Karachi or call at 021-34392159

Ethylene-Glycol-and-Diethylene-Glycol-1Download

Decisions of 52nd Meeting of Medical Device Board (Deficiency letters Local/Import)

Asad Ullah Medical Devices Board, Meeting Minutes, Regulatory Updates

The Medical Device Board (MDB) of Drug Regulatory Authority of Pakistan in its 52nd meeting has deferred the following applications of registration of medical devices due to various deficiencies / shortcomings in the applications dossiers. These applicants are requested to furnish the requisite information / documentations as directed by the Medical Device Board. The detail is provided in the below attachment

Deferred-MDB-52Download

Voluntary Recall Alert: Drug Product; Cytotol 200mcg Tablets (Batch # 176,177,178,179,180) by M/s Saffron Pharmaceutical, Faisalabad

Asad Ullah Product Recalls, Recall Alerts, Safety Info

Voluntary Recall Alert

DRAP Alert NoNoI/S/12-22-42
Action Date20th December 2022
Target Audience1.Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
2.Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospitals and clinics etc.
3. General Public
Product(s) Affected Cytotol 200mcg Tablets,
Active Ingredient(s): Misoprostol
Company: M/s. Saffron Pharmaceutical Faisalabad
Batch No. 176,177,178,179,180
Problem / Issue Saffron Pharmaceuticals (Pvt.) Limited has initiated a voluntary recall of batch No. 176,177,178,179,180 of their product “Cytotol 200mcg Tablet”.
Action Initiated-The manufacturing company is recalling the defected batches of product from the market.

-All Pharmacists and chemists working at distributions and Pharmacies are required to immediately return the stock of above-mentioned batch of product to the supplier / importer / company.

-Distributors and pharmacies are advised to be vigilant and report any suspected batch of product(s) in the supply chain to the DRAP using online form, or through phone at +92 51 910 73 17, or Email at gsms∂dra.gov.pk.

-Regulatory field force of all federating units (DRAP, Provincial Health Departments and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals-DRAP requests increase vigilance within the supply chains of healthcare institutions and hospital pharmacies to identify and return the defective batch(es) of this product to the importer / company.

-Adverse reactions or quality problems experienced with the use of this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using this product bearing the affected batch number(s) and shall contact to their physician or healthcare provider(s) if they have had experienced any problem that may be related to taking or using this product.

-All drug products must be obtained from the authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubt, please seek advice from your pharmacist.
    Voluntary-Recall-of-Cytotol-200mcg-TabletsDownload

      Recall Alert: Drug Product; Tosson 0.4mg SR Capsule by M/s MTI Medical Pvt Ltd, Lahore.

      Asad Ullah Recall Alerts

      Recall Alert

      DRAP Alert NoNoI/S/12-22-41
      Action Date5th December 2022
      Target Audience1. Pharmacists and Chemists at Distributions, Pharmacies and Medical Stores
      2. Healthcare Professionals- Physicians, Pharmacists, and Nurses at Hospitals, Clinics and Healthcare Providing Institutions
      3. General Public
      Product(s) Affected Tosson 0.4mg SR Capsules,
      Active Ingredient(s): Tamsulosin
      Company: M/s. MTI Medical Pvt Ltd, Lahore
      Batch No. 487
      Problem / Issue DTL Lahore has declared the Batch No. 487 of Tosson SR 0.4mg Capsule manufactured by M/s. MTI medical Lahore as substandard drug product.
      Action Initiated-The manufacturing company has been directed to immediately recall the defected batch of product from the market.

      -All Pharmacists and chemists working at distributions and Pharmacies are required to immediately return the stock of above-mentioned batch of product to the supplier / importer / company.

      -Distributors and pharmacies are advised to be vigilant and report any suspected batch of product(s) in the supply chain to the DRAP using online form, or through phone at +92 51 910 73 17, or Email at gsms∂dra.gov.pk.

      -Regulatory field force of all federating units (DRAP, Provincial Health Departments and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
      Advice for Healthcare Professionals-DRAP requests increase vigilance within the supply chains of healthcare institutions and hospital pharmacies to identify and return the defective batch(es) of this product to the importer / company.

      -Adverse reactions or quality problems experienced with the use of this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link.

      -Please click here for further information on problem reporting to DRAP.
      Advice for Consumers-Consumers should stop using this product bearing the affected batch number(s) and shall contact to their physician or healthcare provider(s) if they have had experienced any problem that may be related to taking or using this product.

      -All drug products must be obtained from the authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubt, please seek advice from your pharmacist.
        TOSSON-SR-0.4MG-CAPSULEDownload

        Decisions of 51st Meeting of Medical Device Board (Deficiency letters Local/Import)

        Asad Ullah Medical Devices, Medical Devices Board, Meeting Minutes

        The Medical Device Board (MDB) of Drug Regulatory Authority of Pakistan in its 51st meeting has deferred the following applications of registration of medical devices due to various deficiencies / shortcomings in the applications dossiers. These applicants are requested to furnish the requisite information / documentations as directed by the Medical Device Board. The detail is provided in the below attachment.

        Deferred-MDB-51Download